Bicycle Therapeutics (BCYC) cut 30% of its staff and shelved its Padcev challenger after the FDA rejected the Duravelo-2 trial design for accelerated approval.

Aldeyra (ALDX) received its third CRL for reproxalap in dry eye. The FDA cited the exact same efficacy concerns all three times.

NVIDIA CEO Jensen Huang projected $1 trillion in GPU orders through 2027 at GTC, with Roche and Lilly both flexing their AI infrastructure on stage.

Rhythm (RYTM) faces its Imcivree PDUFA on Friday for acquired hypothalamic obesity. Phase 3 data showed a 16.4% BMI reduction vs. placebo.

Rhythm PDUFA (Friday, March 20): Imcivree sNDA decision for acquired hypothalamic obesity. The sales force has already expanded from 16 to 42 reps for an addressable market estimated at 25,000 to 28,000 patients globally.

NVIDIA GTC Continues (Today and Tomorrow): Healthcare AI sessions run through Thursday. Tuesday's financial analyst Q&A with NVIDIA leadership is worth reviewing for pharma customer growth metrics or healthcare vertical revenue details to pressure-test the GPU arms race.

Orforglipron Decision Window: Lilly's oral GLP-1 pill is under accelerated FDA review via the National Priority Voucher program. Some analysts have modeled a late March potential action date, though no official PDUFA is publicly set.

Rocket Pharma (March 28): Kresladi PDUFA for LAD-I gene therapy. Approval would come with a highly lucrative Priority Review Voucher.

What Happened: Bicycle Therapeutics (BCYC) is cutting roughly 30% of its workforce (~86 people) and shelving zelenectide pevedotin, the Nectin-4 targeting drug conjugate positioned as a credible challenger to Pfizer's Padcev in bladder cancer.

The Regulatory Roadblock: The FDA told Bicycle that the existing Duravelo-2 trial design would not support accelerated approval in metastatic urothelial cancer. Alongside the layoffs, Bicycle is immediately discontinuing Duravelo-3 (breast cancer) and Duravelo-4 (NSCLC).

The Pivot: The restructuring is expected to cut annual operating expenses by roughly 50% and extend the cash runway to 2030. Management now sees real value in nuzefatide pevedotin (BT5528), an EphA2 targeting drug conjugate that just opened a Phase 2 in pancreatic cancer, and their emerging radioligand pipeline with Bayer.

Executive Impact: EphA2 has been historically undruggable, and pancreatic cancer holds massive unmet need. For Pfizer, the Padcev competitive overhang from Bicycle is essentially gone. For BCYC shareholders, this is now a pure "show-me" story with no near-term registrational catalyst.

The Catalyst: Rhythm Pharmaceuticals (RYTM) faces its March 20 PDUFA decision date for the sNDA seeking to expand Imcivree (setmelanotide) into acquired hypothalamic obesity (HO).

The Data: The company recently reported additional Phase 3 TRANSCEND data showing a mean BMI reduction of 16.4% for setmelanotide compared to a 2.4% BMI increase on placebo at 52 weeks. Responder rates showed 80% of patients achieving greater than 5% BMI reduction.

The Context: The FDA extended the review by three months in November after requesting additional sensitivity analyses, but no new clinical data was required and no safety or manufacturing issues were flagged. Imcivree generated $194 million in 2025 revenue (+50% YoY); an HO approval would be the drug's fourth indication and could meaningfully accelerate that trajectory.

What Happened: The FDA issued a third Complete Response Letter for Aldeyra's (ALDX) reproxalap NDA in dry eye disease, citing a lack of substantial evidence of efficacy and calling the inconsistency of study results into question. This is the third rejection since November 2023.

The Disconnect: The FDA provided draft labeling during the review in December 2025 and March 2026, which some wrongly interpreted as a positive signal. Aldeyra argues reproxalap shows clinical activity within minutes of administration (unlike existing treatments that take weeks).

What's Next: Aldeyra plans to request a Type A meeting and currently does not intend to run additional clinical trials. The FDA has evaluated this data package three separate times and reached the identical conclusion.

The Keynote: At NVIDIA's GTC 2026 keynote on Monday, CEO Jensen Huang projected $1 trillion in cumulative purchase orders for Blackwell and Vera Rubin chips through 2027.

The Pharma Angle: Healthcare and drug discovery received significant stage time. Roche's deployment of 3,500+ Blackwell GPUs for its "hybrid cloud AI factory" was highlighted, along with Lilly's LillyPod AI infrastructure. NVIDIA introduced new tools across its BioNeMo platform for molecular simulation and protein modeling.

Executive Impact: The healthcare GPU buildout is massive. However, nobody in the industry has yet attributed a single approved, commercialized drug to AI-driven discovery in a way that clears the fundamental ROI bar. The infrastructure is racing ahead of the clinical proof, and closing that gap will define pharma AI sentiment for the rest of 2026.

The Catalyst: Eli Lilly's oral GLP-1 pill, orforglipron, is currently under FDA review with a potential decision in late March 2026, accelerated via the Commissioner's National Priority Voucher. The NDA was filed for obesity, with a separate type 2 diabetes submission planned.

The Market: This is the most commercially significant regulatory catalyst of the quarter, with GlobalData forecasting $13 billion in peak sales by 2031. The oral format is critical to address poor real-world GLP-1 adherence.

The Pricing: Lilly has committed to a $149 starting price for the lowest dose through LillyDirect. With Novo Nordisk's oral Wegovy also under FDA review, both pills could potentially reach the market simultaneously, setting up a massive head-to-head pricing and access war.